Drug repurposing strategies of relevance for Parkinson’s disease
Authors:
Open Access
- 26 July 2021
- journal article
- review article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (4) , e00841
Abstract
Parkinson's disease is a highly disabling, progressive neurodegenerative disease that manifests as a mix of motor and non‐motor signs. Although we are equipped with some symptomatic treatments, especially for the motor signs of the disease, there are still no established disease‐modifying drugs so the disease progresses unchecked. Standard drug discovery programs for disease‐modifying therapies have provided key insights into the pathogenesis of Parkinson's disease but, of the many positive candidates identified in pre‐clinical studies, none has yet translated into a successful clinically efficacious drug. Given the huge cost of drug discovery programs, it is not surprising that much attention has turned toward repurposing strategies. The trialing of an established therapeutic has the advantage of bypassing the need for preclinical safety testing and formulation optimization, thereby cutting both time and costs involved in getting a treatment to the clinic. Additional reduced failure rates for repurposed drugs are also a potential bonus. Many different strategies for drug repurposing are open to researchers in the Parkinson's disease field. Some of these have already proven effective in identifying suitable drugs for clinical trials, lending support to such approaches. In this review, we present a summary of the different strategies for drug repurposing, from large‐scale epidemiological correlation analysis through to single‐gene transcriptional approaches. We provide examples of past or ongoing studies adopting each strategy, where these exist. For strategies that have yet to be applied to Parkinson's disease, their utility is illustrated using examples taken from other disorders.Keywords
Funding Information
- Parkinson's UK (G‐1801)
- Medical Research Council
This publication has 83 references indexed in Scilit:
- Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral SclerosisPLOS ONE, 2013
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression DataScience Translational Medicine, 2011
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's diseaseNeurobiology of Disease, 2011
- mRNA Expression Signatures of Human Skeletal Muscle Atrophy Identify a Natural Compound that Increases Muscle MassCell Metabolism, 2011
- Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotectionBritish Journal of Pharmacology, 2010
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher DiseaseJournal of Biological Chemistry, 2009
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismProceedings of the National Academy of Sciences, 2009
- Drug target validation and identification of secondary drug target effects using DNA microarraysNature Medicine, 1998